The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of cabozantinib (Cabo) and pembrolizumab (Pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) resistant or refractory to immune checkpoint inhibitors (ICI).
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - Array BioPharma; Eisai; Exelixis; Genentech/Roche; QED Therapeutics; Signatera
Speakers' Bureau - Amgen; Deciphera; Eisai; Exelixis; Genentech/Roche; ipsen; Natera; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Joseph Chao
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Geneos; Guardant Health; Merck; Roche
Speakers' Bureau - Bristol Myers Squibb; Merck
Research Funding - Brooklyn Immunotherapeutics (Inst); Merck (Inst); Novonco Therapeutics (Inst)
Other Relationship - Daiichi Sankyo; Yiviva
 
Fa-Chyi Lee
No Relationships to Disclose
 
Thomas H. Taylor
No Relationships to Disclose
 
Kristen Neumann
No Relationships to Disclose
 
May T Cho
Employment - Replimune
Stock and Other Ownership Interests - Replimune
Honoraria - Array BioPharma; Daiichi Sankyo; Exelixis; Taiho Oncology
Consulting or Advisory Role - AstraZeneca; E.R. Squibb Sons, LLC; Eisai
Speakers' Bureau - Helsinn Therapeutics
Travel, Accommodations, Expenses - Seagen